Lee Jong-Sung, Park Jong-Il, Kim Sun-Hee, Lee Hye-Young, Hwang Zai-Zhi, Park Cheol-Beom, Sohn Tsang-Uk, Shin Sunhee, Kang Jong-Koo, Kim Yun-Bae
Biotoxtech Co., Ltd., Ochang Scientific and Industrial Complex, Cheongwon, Korea.
J Toxicol Sci. 2004 Dec;29(5):555-69. doi: 10.2131/jts.29.555.
Single- and 13-week repeated-dose toxicities of Geranti Bio-Ge Yeast, organic germanium fortified yeasts, were investigated in dogs. Both sexes of Beagle dogs were orally administered once at a dose of 2,000 mg/kg in single-dose toxicity or daily for 13 weeks at doses of 500, 1,000 or 2,000 mg/kg in repeated-dose toxicity tests. In single-dose toxicity test, no animal dead, moribund, or showing clinical signs or changes in body weight gain was found. In repeated-dose toxicity study, there were no considerable changes in ophthalmoscopy and urinalysis. Several alterations were observed in electrocardiography, hematology and blood biochemistry, including heart rate, R-R interval, QT correcting, reticulocytes, activated partial thromboplastin time and albumin/globulin ratio in only male dogs, but not in females, administered with Geranti Bio-Ge Yeast in a dose-independent manner. In gross findings, several cases of abnormal findings were observed in both control and treatment groups, showing diffuse dark brown to black discoloration of liver, in a dose-independent manner. In microscopic examination, mild lesions, including cholestasis and inflammatory cell foci in liver, kidneys and prostate, were found sporadically in both control and treatment groups. In spite of some alterations in electrocardiography, hematology, blood biochemistry, gross and microscopic findings, such effects were not considered to include toxicopathological significance, based on the marginal changes within normal ranges and lack of dose-dependency, consistent time-course and gender relationship. Taken together, it is suggested that no observed adverse effect level (NOAEL) of Geranti Bio-Ge Yeast is considered to be 2,000 mg/kg in dogs, and that long-term treatment in clinical trials might not exert adverse effects.
对含有机锗的Geranti生物锗酵母进行了犬单次及13周重复给药毒性研究。在单次给药毒性试验中,比格犬雌雄两性均按2000mg/kg的剂量口服给药一次;在重复给药毒性试验中,按500、1000或2000mg/kg的剂量每日口服给药,持续13周。在单次给药毒性试验中,未发现动物死亡、濒死,也未观察到临床症状或体重增加有变化。在重复给药毒性研究中,眼科检查和尿液分析未出现明显变化。在心电图、血液学和血液生化方面观察到一些改变,包括仅在接受Geranti生物锗酵母给药的雄性犬中出现心率、R-R间期、QT校正、网织红细胞、活化部分凝血活酶时间和白蛋白/球蛋白比值的变化,雌性犬未出现变化,且这些变化与剂量无关。大体检查发现,对照组和治疗组均有几例出现异常结果,表现为肝脏呈弥漫性暗褐色至黑色变色,且与剂量无关。显微镜检查发现,对照组和治疗组均偶尔出现轻度病变,包括肝脏、肾脏和前列腺的胆汁淤积和炎症细胞灶。尽管在心电图、血液学、血液生化、大体和显微镜检查方面有一些改变,但基于正常范围内的微小变化以及缺乏剂量依赖性、一致的时间进程和性别关系,这些影响不被认为具有毒理学病理意义。综上所述,提示Geranti生物锗酵母在犬中的未观察到有害作用水平(NOAEL)为2000mg/kg,且在临床试验中的长期治疗可能不会产生不良反应。